FDA expands Enhertu use in early HER2-positive breast cancer
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
Subscribe To Our Newsletter & Stay Updated